Glycerin

Glycerin

SCHEMBL1663414

CC1CCC(C(C)C)C(OC(=O)O)C1.OCC(O)CO

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.51
CYP19A1 P11511 2/20 0.49
ALDH1A1 P00352 7/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 2/20 0.45
KDM4E B2RXH2 1/20 0.43
APOBEC3A P31941 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
MAPT P10636 2/20 0.43
TSHR P16473 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
USP2 O75604 1/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NTSR1 P30989 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propylene Glycol SCHEMBL906429 0.93 CYP19A1 (0.53) EPHX1CYP19A1ALDH1A1HPGDLMNA
Ethylene Glycol SCHEMBL27579683 0.90 EPHX1 (0.55) EPHX1CYP19A1ALDH1A1HPGDLMNA
Ethylene Glycol SCHEMBL906564 0.90 EPHX1 (0.55) EPHX1CYP19A1ALDH1A1HPGDLMNA
Ethylene Glycol SCHEMBL28227214 0.90 EPHX1 (0.55) EPHX1CYP19A1ALDH1A1HPGDLMNA
SCHEMBL13460250 0.89 EPHX1 (0.60) EPHX1CYP19A1ALDH1A1HPGDLMNA
SCHEMBL16610788 0.89 EPHX1 (0.60) EPHX1CYP19A1ALDH1A1HPGDLMNA
SCHEMBL1075940 0.89 EPHX1 (0.60) EPHX1CYP19A1ALDH1A1HPGDLMNA
SCHEMBL13460327 0.89 EPHX1 (0.60) EPHX1CYP19A1ALDH1A1HPGDLMNA
SCHEMBL5125214 0.89 EPHX1 (0.60) EPHX1CYP19A1ALDH1A1HPGDLMNA
Bicarbonate SCHEMBL28880176 0.88 EPHX1 (0.53) EPHX1CYP19A1ALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2026-02-19 US claimed
US-20250325463-A1 COMPOSITIONS (III) SYMRISE AG (DE) 2025-10-23 US claimed
EP-4622621-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL Symrise AG (DE) 2025-10-01 EP claimed
EP-4472606-A1 COMPOSITIONS (III) Symrise AG (DE) 2024-12-11 EP claimed
US-20240358611-A1 COMPOSITIONS SYMRISE AG (DE) 2024-10-31 US claimed
EP-4429465-A1 COMPOSITIONS COMPRISING TRPM8 AGONISTIC COOLING AGENTS Symrise AG (DE) 2024-09-18 EP claimed
US-20240225915-A1 COMPOSITIONS FOR FIGHTING MALODORS SYMRISE AG (DE) 2024-07-11 US claimed
EP-4387587-A1 COMPOSITIONS Symrise AG (DE) 2024-06-26 EP claimed
WO-2024110515-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL SYMRISE AG (DE) 2024-05-30 WO claimed
EP-4351667-A1 COMPOSITIONS FOR FIGHTING MALODORS Symrise AG (DE) 2024-04-17 EP claimed
WO-2023083445-A1 COMPOSITIONS COMPRISING TRPM8 AGONISTIC COOLING AGENTS SYMRISE AG (DE) 2023-05-19 WO claimed
WO-2023021012-A1 COMPOSITIONS SYMRISE AG (DE) 2023-02-23 WO claimed
WO-2022258189-A1 COMPOSITIONS FOR FIGHTING MALODORS SYMRISE AG (DE) 2022-12-15 WO claimed
EP-3081207-B1 USE OF A LIPOSOME COMPOSITION SYMRISE AG (DE) 2022-09-21 EP claimed
WO-2022122144-A1 A METHOD FOR FIGHTING MICROORGANISMS USING MENTHOL DERIVATIVES SYMRISE AG (DE) 2022-06-16 WO claimed
EP-3687311-A1 AMIDES FOR GENERATING A TRIGEMINAL EFFECT Symrise AG (DE) 2020-08-05 EP claimed
EP-3142499-B1 HOMOVANILLIC ACID ESTERS, IN PARTICULAR FOR ACHIEVING AN IMPRESSION OF HEAT AND/OR SPICINESS SYMRISE AG (DE) 2019-10-30 EP claimed
US-10392371-B2 Compounds useful as modulators of TRPM8 SENOMYX, INC. (US) 2019-08-27 US claimed
WO-2016166038-A1 WHITENING COMPOSITIONS SYMRISE AG (DE) 2016-10-20 WO claimed
EP-3081207-A1 WHITENING COMPOSITIONS Symrise AG (DE) 2016-10-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358611-A1 COMPOSITIONS AZI2, NISCH, CIP2A EPHX1 2269/4885CYP19A1 619/4885ALDH1A1 815/4885
US-10392371-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM4, TRPM6 EPHX1 4010/4885CYP19A1 4071/4885ALDH1A1 3726/4885
US-20260047994-A1 AN ACTIVE COMPOSITION COMPRISING RETINOL RBP4, LRAT, RARB EPHX1 721/4885CYP19A1 1677/4885ALDH1A1 156/4885
US-20250325463-A1 COMPOSITIONS (III) NISCH, TAS1R3, TAS2R3 EPHX1 3052/4885CYP19A1 557/4885ALDH1A1 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.